CSBR
Income statement / Annual
Last year (2025), Champions Oncology, Inc.'s total revenue was $56.94 M,
an increase of 13.54% from the previous year.
In 2025, Champions Oncology, Inc.'s net income was $4.70 M.
See Champions Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
04/30/2025 |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
| Operating Revenue |
$56.94 M |
$50.16 M |
$53.87 M |
$49.11 M |
$41.04 M |
$32.12 M |
$27.07 M |
$20.24 M |
$15.41 M |
$11.18 M |
| Cost of Revenue |
$28.39 M
|
$29.40 M
|
$29.53 M
|
$23.63 M
|
$21.47 M
|
$16.88 M
|
$14.27 M
|
$10.55 M
|
$9.70 M
|
$8.69 M
|
| Gross Profit |
$28.56 M
|
$20.75 M
|
$24.34 M
|
$25.48 M
|
$19.57 M
|
$15.24 M
|
$12.80 M
|
$9.69 M
|
$5.71 M
|
$2.50 M
|
| Gross Profit Ratio |
0.5
|
0.41
|
0.45
|
0.52
|
0.48
|
0.47
|
0.47
|
0.48
|
0.37
|
0.22
|
| Research and Development Expenses |
$6.83 M
|
$9.54 M
|
$11.55 M
|
$9.37 M
|
$7.20 M
|
$5.85 M
|
$4.80 M
|
$4.40 M
|
$4.29 M
|
$4.19 M
|
| General & Administrative Expenses |
$9.34 M
|
$11.07 M
|
$10.24 M
|
$9.12 M
|
$6.51 M
|
$6.61 M
|
$4.68 M
|
$4.07 M
|
$4.96 M
|
$5.17 M
|
| Selling & Marketing Expenses |
$7.55 M
|
$7.06 M
|
$7.00 M
|
$6.38 M
|
$5.52 M
|
$4.24 M
|
$3.06 M
|
$2.57 M
|
$3.26 M
|
$3.45 M
|
| Selling, General & Administrative Expenses |
$16.88 M
|
$18.13 M
|
$17.24 M
|
$15.50 M
|
$12.03 M
|
$10.86 M
|
$7.73 M
|
$6.64 M
|
$8.22 M
|
$8.62 M
|
| Other Expenses |
$293.00 K
|
$435.00 K
|
-$11.00 K
|
-$24.00 K
|
$71.00 K
|
-$42.00 K
|
-$39.00 K
|
-$88.00 K
|
-$56.00 K
|
-$38.00 K
|
| Operating Expenses |
$24.00 M
|
$28.11 M
|
$28.79 M
|
$24.87 M
|
$19.23 M
|
$16.71 M
|
$12.53 M
|
$11.04 M
|
$12.52 M
|
$12.81 M
|
| Cost And Expenses |
$52.39 M
|
$57.51 M
|
$58.32 M
|
$48.50 M
|
$40.70 M
|
$33.59 M
|
$26.80 M
|
$21.60 M
|
$22.22 M
|
$21.50 M
|
| Interest Income |
$87.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$27.00 K
|
$0.00
|
$0.00
|
$24.00 K
|
$0.00
|
$0.00
|
$39.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.64 M
|
$1.87 M
|
$3.20 M
|
$2.41 M
|
$1.58 M
|
$1.23 M
|
$606.00 K
|
$360.00 K
|
$168.00 K
|
$156.00 K
|
| EBITDA |
$6.49 M |
-$5.05 M |
-$2.07 M |
$2.23 M |
$366.00 K |
-$735.00 K |
$837.00 K |
-$994.00 K |
-$6.64 M |
-$10.16 M |
| EBITDA Ratio |
0.11
|
-0.1
|
-0.04
|
0.05
|
0.01
|
-0.02
|
0.03
|
-0.05
|
-0.43
|
-0.91
|
| Operating Income Ratio |
0.08
|
-0.15
|
-0.08
|
0.01
|
0.01
|
-0.05
|
0.01
|
-0.07
|
-0.44
|
-0.92
|
| Total Other Income/Expenses Net |
$73.00 K
|
$48.00 K
|
-$11.00 K
|
-$24.00 K
|
$99.00 K
|
-$495.00 K
|
-$39.00 K
|
-$89.00 K
|
-$56.00 K
|
-$38.00 K
|
| Income Before Tax |
$4.63 M
|
-$7.31 M
|
-$5.27 M
|
$583.00 K
|
$437.00 K
|
-$1.85 M
|
$231.00 K
|
-$1.44 M
|
-$6.87 M
|
-$10.35 M
|
| Income Before Tax Ratio |
0.08
|
-0.15
|
-0.1
|
0.01
|
0.01
|
-0.06
|
0.01
|
-0.07
|
-0.45
|
-0.93
|
| Income Tax Expense |
-$75.00 K
|
-$32.00 K
|
$68.00 K
|
$35.00 K
|
$75.00 K
|
$130.00 K
|
$103.00 K
|
$63.00 K
|
$19.00 K
|
$92.00 K
|
| Net Income |
$4.70 M
|
-$7.28 M
|
-$5.34 M
|
$548.00 K
|
$362.00 K
|
-$1.98 M
|
$128.00 K
|
-$1.51 M
|
-$6.88 M
|
-$10.45 M
|
| Net Income Ratio |
0.08
|
-0.15
|
-0.1
|
0.01
|
0.01
|
-0.06
|
0
|
-0.07
|
-0.45
|
-0.93
|
| EPS |
0.34 |
-0.54 |
-0.39 |
0.0415 |
0.0276 |
-0.17 |
0.0113 |
-0.14 |
-0.64 |
-1.2 |
| EPS Diluted |
0.33 |
-0.54 |
-0.39 |
0.0387 |
0.0248 |
-0.17 |
0.0091 |
-0.14 |
-0.63 |
-1.2 |
| Weighted Average Shares Out |
$13.66 M
|
$13.55 M
|
$13.54 M
|
$13.20 M
|
$13.14 M
|
$11.84 M
|
$11.34 M
|
$10.99 M
|
$10.68 M
|
$8.70 M
|
| Weighted Average Shares Out Diluted |
$14.27 M
|
$13.55 M
|
$13.54 M
|
$14.16 M
|
$14.57 M
|
$11.84 M
|
$14.10 M
|
$11.00 M
|
$10.98 M
|
$8.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
